Wilkinson Narcisse is currently working as a Clinical Trial Leader for Scimega Research Inc, CRO specializing in Oncology. He holds more than 15 years’ experience of clinical research (Phase I, II, III, and IV) monitoring and management in Canada & US with different CRO’s including Scimega Research, C3i-CRO, Covance, and PRA Health Sciences. Wilkinson Narcisse has also previously held the position of Director Clinical Operations & project management, Clinical Operation manager, and Senior Clinical Research Associate at C3i-CRO, Director Business Development at MDS Pharma Services and Scientific Project Manager at Algorithme pharma (Altasciences).

Wilkinson has completed a BSc. In Microbiology with an M.Sc. In Reproductive Immunology from Laval University, Canada.

In addition to his solid knowledge about the pharmaceutical industry, the clinical trials process, the drug development process, and the CRO business, Wilkinson has experience with the following Clinical Indications: Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Renal cell Carcinoma, Breast Cancer, Ovarian and Colorectal Cancer, Small cell Lung Cancer, Prostate Cancer, Pancreatic Cancer, Dermatology (Skin Disease, Antibiotic), and Infectious Disease (Hepatitis C).